Healthcare Industry News: Bristol-Myers Squibb
News Release - February 15, 2011
Baxter Appoints Two Corporate OfficersDEERFIELD, Ill.--(Healthcare Sales & Marketing Network)-- Baxter International Inc. (NYSE:BAX ) announced today that its Board of Directors has elected two new corporate officers of the company.
Paul E. Martin, who joined Baxter earlier this year as Chief Information Officer, has been appointed to serve as an officer of the company. Martin joined Baxter from Rexam PLC, the U.K.-based packaging manufacturer, where he held the position of Group Chief Information Officer, responsible for all Information Technology functions across more than 20 countries. During his eleven years with Rexam, Martin served in a variety of key senior management positions including Vice President and CIO Beverage Can Americas and Head of Information Technology for American National Can (acquired by Rexam PLC). Prior to Rexam, he worked for The CIT Group, BNSF Railway and Frito Lay. Martin received his degree in Management Information Systems from Western Kentucky University.
Wolf F. Kupatt, who currently serves as president of Latin America and Canada, has also been appointed to serve as an officer of the company. Kupatt was promoted to his current position in 2010, after serving as general manager for Baxter’s operations in Germany. Before joining Baxter, Kupatt served as vice president, Primary Care, Germany, for Bristol-Myers Squibb from 2002 to 2007. Between 1989 and 2002, Kupatt served in a variety of senior management roles for the Roche group in Germany, Ecuador and Colombia. Kupatt received a degree in Medicine from the University of Bonn in Germany in 1986. He has been a member of the board of directors of the BPI Pharmaceutical Industry Association since 2007.
“Paul and Wolf both bring extensive global experience, keen expertise in their respective fields, and outstanding leadership capabilities to our executive team,” said Robert L. Parkinson, Jr., chairman and chief executive officer.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.